Global GBS (Group B Streptococcus) Testing Market Growth 2024-2030

Global GBS (Group B Streptococcus) Testing Market Growth 2024-2030

The scientific name of GBS is Streptococcus agalactiae, also known as group B Streptococcus. It normally lives in the vagina and rectum. It is an opportunistic pathogenic bacteria. Invasive infections are most common in neonates, the elderly, and those with predisposing factors (i.e., pregnancy, diabetes, and immunocompromise). Generally, GBS infection in normal healthy people does not cause illness.According to research, about 10% to 30% of pregnant women have GBS vaginally resident, and 40% to 70% of them will be passed to their newborns during delivery. If newborns carry GBS, about 1% to 3% will develop early invasive infection, of which 5% will lead to death. Infections in pregnant women manifest as bacteremia, urinary tract infection, fetal membrane infection, endometrial infection and wound infection.

The global GBS (Group B Streptococcus) Testing market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “GBS (Group B Streptococcus) Testing Industry Forecast” looks at past sales and reviews total world GBS (Group B Streptococcus) Testing sales in 2023, providing a comprehensive analysis by region and market sector of projected GBS (Group B Streptococcus) Testing sales for 2024 through 2030. With GBS (Group B Streptococcus) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GBS (Group B Streptococcus) Testing industry.

This Insight Report provides a comprehensive analysis of the global GBS (Group B Streptococcus) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GBS (Group B Streptococcus) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GBS (Group B Streptococcus) Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GBS (Group B Streptococcus) Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GBS (Group B Streptococcus) Testing.

United States market for GBS (Group B Streptococcus) Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for GBS (Group B Streptococcus) Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for GBS (Group B Streptococcus) Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key GBS (Group B Streptococcus) Testing players cover Zhuhai DL Biotech, Meikang Biotechnology, Biomerieux, Shandong Boko Biotechnology and Barrett Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of GBS (Group B Streptococcus) Testing market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Microbiological Culture Method
Fluorescence Quantitative PCR Method
Immunochromatography
Other

Segmentation by application
Newborn
Elderly
Pregnant Woman
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Zhuhai DL Biotech
Meikang Biotechnology
Biomerieux
Shandong Boko Biotechnology
Barrett Bio
Luminex
Guangdong Sunshine Biotechnology
Shengxiang Biotechnology
Borcheng
Guangzhou Huaao Biotechnology
Kayudi Biotechnology
Suzhou Tianlong Biotechnology
Beijing KingWolf Biology
Guangzhou Micron Biotechnology
Shanghai Suchuang Diagnostic Products
Certest Biotec S.L.
Thermo Fisher
AtilaBiosystems

Key Questions Addressed in this Report

What is the 10-year outlook for the global GBS (Group B Streptococcus) Testing market?

What factors are driving GBS (Group B Streptococcus) Testing market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GBS (Group B Streptococcus) Testing market opportunities vary by end market size?

How does GBS (Group B Streptococcus) Testing break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.